ClinConnect ClinConnect Logo
Search / Trial NCT03447938

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Feb 21, 2018

Trial Information

Current as of July 06, 2025

Recruiting

Keywords

ClinConnect Summary

The MIST Trial is studying two methods of heart surgery for patients with coronary artery disease, a condition where blood vessels in the heart become blocked. One method is called Minimally Invasive Coronary Surgery (MICS CABG), which uses a small cut in the chest to perform the surgery. The other is conventional sternotomy CABG, which involves a larger incision down the middle of the chest. The goal of the trial is to see which method helps patients recover faster and improves their quality of life after surgery.

To participate in this trial, you need to be at least 18 years old and have significant blockages in your coronary arteries that require surgery. If you are chosen, you will complete quality of life questionnaires at different points after your surgery to help researchers understand how you are feeling and recovering. It's important to know that this study is currently recruiting participants, and your involvement could contribute to better treatment options for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years of age or older
  • Angiographically-confirmed multi-vessel coronary artery disease lesions with \>=70% in at least 2 major epicardial vessels in 2 or more coronary artery territories (left anterior descending (LAD), circumflex (CX) and right coronary artery (RCA)) OR lesions \>=50% in the left main (LM)
  • Patients who, in the opinion of the investigator, are amenable for coronary surgery through either median sternotomy or minimally-invasive approach.
  • Patients who are willing and able to comply with all follow-up study visits.
  • Exclusion Criteria:
  • \<18 years of age
  • concomitant cardiac procedure with CABG (e.g. valve repair or replacement)
  • Previous cardiac surgery, mediastinal irradiation, or significant trauma to the chest
  • Contra-indications for MICS CABG, including: severe pectus excavatum; severe pulmonary disease; hemodynamically significant left subclavian stenosis; morbid obesity; severe left ventricular (LV) dysfunction; no adequate PDA or marginal branch target; absence of femoral pulse bilaterally.
  • Contraindications for conventional CABG via sternotomy
  • Concomitant life-threatening disease likely to limit life expectancy to \<2 years
  • Emergency CABG with hemodynamic compromise
  • Inability to provide informed consent.

About Ottawa Heart Institute Research Corporation

The Ottawa Heart Institute Research Corporation is a leading clinical research organization dedicated to advancing cardiovascular medicine through innovative research and clinical trials. Affiliated with the renowned University of Ottawa Heart Institute, the corporation focuses on conducting high-quality, ethically-driven studies that aim to improve patient outcomes and enhance understanding of heart-related diseases. With a commitment to collaboration and excellence, the organization engages multidisciplinary teams of researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective therapies and interventions for cardiovascular health.

Locations

La Crosse, Wisconsin, United States

Pittsburgh, Pennsylvania, United States

Ottawa, Ontario, Canada

Leuven, , Belgium

Toronto, Ontario, Canada

Taipei, , Taiwan

Houston, Texas, United States

Leipzig, Saxony, Germany

New Delhi, Delhi, India

Stuttgart, , Germany

Fresno, California, United States

Charlotte, North Carolina, United States

London, Ontario, Canada

Wuhan, Hubei Sheng, China

Jilin, Jilin, China

Bangalore, Karnataka, India

Ichinomiya, Aichi, Japan

New Delhi, Delhi, India

Urayasu, Chiba, Japan

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Marc Ruel, MD

Principal Investigator

Ottawa Heart Institute Research Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials